The pharmaceutical company Moderna disclosed on Friday that the U.S. Department of Health and Human Services will grant them $590 million to further develop a vaccine against bird flu. Moderna intends to progress its research on the mRNA vaccine to a Phase 3 trial following promising outcomes in earlier phases, which it intends to present at an upcoming scientific conference.
In a separate initiative, the Biden administration recently announced over $300 million in funding to support surveillance and preparedness efforts for bird flu. Secretary of Health and Human Services Xavier Becerra emphasized that expediting the development of new vaccines will enable Americans to proactively safeguard their health and well-being.